Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Lisata Therapeutics (LSTA) and Acurx Pharmaceuticals (ACXP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Definitive Healthcare Corp (DH – Research Report), Lisata Therapeutics (LSTA – Research Report) and Acurx Pharmaceuticals (ACXP – Research Report).

Definitive Healthcare Corp (DH)

Barclays analyst Saket Kalia upgraded Definitive Healthcare Corp to Hold on January 17 and set a price target of $10.00. The company’s shares closed last Monday at $9.06.

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 15.4% and a 61.6% success rate. Kalia covers the Technology sector, focusing on stocks such as Procore Technologies, CrowdStrike Holdings, and Palo Alto Networks.

Definitive Healthcare Corp has an analyst consensus of Moderate Buy, with a price target consensus of $9.61, implying a 7.3% upside from current levels. In a report issued on January 4, Canaccord Genuity also downgraded the stock to Hold with a $10.00 price target.

See the top stocks recommended by analysts >>

Lisata Therapeutics (LSTA)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics on January 17 and set a price target of $15.00. The company’s shares closed last Monday at $2.97.

According to TipRanks.com, Pantginis is a 3-star analyst with an average return of 0.5% and a 40.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Cadrenal Therapeutics, Inc., and Actinium Pharmaceuticals.

Lisata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.

Acurx Pharmaceuticals (ACXP)

In a report issued on January 17, Ed Arce from H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Monday at $3.72.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.4% and a 40.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Acurx Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DH:

• Definitive Healthcare downgraded to Hold from Buy at Needham
• Definitive Healthcare price target lowered to $11 from $12 at Stifel
• Definitive Healthcare price target lowered to $9 from $10 at Canaccord
• Definitive Healthcare sees FY24 revenue up 5%-7%, consensus $273.5M
• Definitive Healthcare Announces CEO Transition